GLP1R and type 2 diabetes mellitus: Notably, glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for the treatment of type 2 diabetes mellitus (T2DM) and obesity, may be associated with gastrointestinal side effects including nausea, delayed gastric emptying, and heartburn, [12,13,14,15] stemming from their impact on delaying gastric motility and increasing gastric acid exposure in the esophagus [12].